Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.38 |
| ▸ | RORC | P51449 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RARG | P13631 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | STAT1 | P42224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2677079 | 0.81 | PDE5A (0.44) | SCN9ARORCALDH1A1KMT2ARARG | |
| SCHEMBL12305051 | 0.81 | MAPK1 (0.47) | ALDH1A1NPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL14333535 | 0.79 | ADORA3 (0.43) | SCN9ARORCALDH1A1KMT2ANPC1 | |
| SCHEMBL14406063 | 0.74 | SCN9A (0.53) | SCN9ARORCALDH1A1GAASMN1; SMN2 | |
| SCHEMBL13036488 | 0.71 | KDM4E (0.59) | ALDH1A1KMT2ARAB9AGAASMN1; SMN2 | |
| SCHEMBL29218170 | 0.67 | FGFR1 (0.53) | KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24934016 | 0.66 | GAA (0.41) | ALDH1A1KMT2ANPC1RAB9AGAA | |
| SCHEMBL30163066 | 0.66 | GAA (0.41) | ALDH1A1KMT2ANPC1RAB9AGAA | |
| SCHEMBL30163022 | 0.65 | NPC1 (0.42) | KMT2ANPC1RAB9A | |
| SCHEMBL30163006 | 0.65 | GABRP (0.36) | ALDH1A1KMT2ANPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD4, CD47 | SCN9A 4736/4885RORC 10/4885ALDH1A1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.